Novel Insights into Factor D Inhibition

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 9

PMID 35806224

Authors

Eleni Gavriilaki

Anna Papakonstantinou

Konstantinos A Agrios

Affiliations

Soon will be listed here.

Abstract

Complement-mediated diseases or complementopathies, such as Paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), and transplant-associated thrombotic microangiopathy (TA-TMA), demand advanced complement diagnostics and therapeutics be adopted in a vast field of medical specialties, such as hematology, transplantation, rheumatology, and nephrology. The miracle of complement inhibitors as "orphan drugs" has dramatically improved morbidity and mortality in patients with otherwise life-threatening complementopathies. Efficacy has been significantly improved by upstream inhibition in patients with PNH. Different molecules may exert diverse characteristics in vitro and in vivo. Further studies remain to show safety and efficacy of upstream inhibition in other complementopathies. In addition, cost and availability issues are major drawbacks of current treatments. Therefore, further developments are warranted to address the unmet clinical needs in the field of complementopathies. This state-of-the-art narrative review aims to delineate novel insights into factor D inhibition as a promising target for complementopathies.

Citing Articles

Highlights on U.S. FDA-approved halogen-containing drugs in 2024.

Ali S, Tian X, Meccia S, Zhou J Eur J Med Chem. 2025; 287:117380.

PMID: 39947048 PMC: 11846695. DOI: 10.1016/j.ejmech.2025.117380.

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.

Kokoris S, Polyviou A, Evangelidis P, Grouzi E, Valsami S, Tragiannidis K Int J Mol Sci. 2024; 25(22).

PMID: 39596172 PMC: 11594924. DOI: 10.3390/ijms252212104.

Role of complement factor D in cardiovascular and metabolic diseases.

Kong Y, Wang N, Tong Z, Wang D, Wang P, Yang Q Front Immunol. 2024; 15:1453030.

PMID: 39416783 PMC: 11479899. DOI: 10.3389/fimmu.2024.1453030.

Hematology: the specialty with a record number of new approvals.

Gavriilaki E Front Med (Lausanne). 2024; 11:1385052.

PMID: 38487026 PMC: 10937422. DOI: 10.3389/fmed.2024.1385052.

DNA Methylation Changes in Blood Cells of Fibromyalgia and Chronic Fatigue Syndrome Patients.

Przybylowicz P, Sokolowska K, Rola H, Wojdacz T J Pain Res. 2023; 16:4025-4036.

PMID: 38054109 PMC: 10695140. DOI: 10.2147/JPR.S439412.

References

Maibaum J, Liao S, Vulpetti A, Ostermann N, Randl S, Rudisser S . Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol. 2016; 12(12):1105-1110. DOI: 10.1038/nchembio.2208. View

Ganguly H, Basu G . Conformational landscape of substituted prolines. Biophys Rev. 2020; 12(1):25-39. PMC: 7040156. DOI: 10.1007/s12551-020-00621-8. View

Karki R, Powers J, Mainolfi N, Anderson K, Belanger D, Liu D . Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway. J Med Chem. 2019; 62(9):4656-4668. DOI: 10.1021/acs.jmedchem.9b00271. View

Gavriilaki E, Peffault de Latour R, Risitano A . Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood. 2021; 139(25):3571-3582. DOI: 10.1182/blood.2021012860. View

Volanakis J, Narayana S . Complement factor D, a novel serine protease. Protein Sci. 1996; 5(4):553-64. PMC: 2143395. DOI: 10.1002/pro.5560050401. View

Kulasekararaj A, Risitano A, Maciejewski J, Notaro R, Browett P, Lee J . Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021; 138(20):1928-1938. PMC: 8602931. DOI: 10.1182/blood.2021011388. View

Risitano A, Kulasekararaj A, Lee J, Maciejewski J, Notaro R, Brodsky R . Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2020; 106(12):3188-3197. PMC: 8634185. DOI: 10.3324/haematol.2020.261826. View

Sanderson P . Small, noncovalent serine protease inhibitors. Med Res Rev. 1999; 19(2):179-97. DOI: 10.1002/(sici)1098-1128(199903)19:2<179::aid-med4>3.0.co;2-5. View

Risitano A, Marotta S . Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol. 2016; 28(3):223-40. DOI: 10.1016/j.smim.2016.05.001. View

10.

Forneris F, Ricklin D, Wu J, Tzekou A, Wallace R, Lambris J . Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science. 2011; 330(6012):1816-20. PMC: 3087196. DOI: 10.1126/science.1195821. View

11.

Smith R, Appel G, Blom A, Cook H, DAgati V, Fakhouri F . C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019; 15(3):129-143. PMC: 6876298. DOI: 10.1038/s41581-018-0107-2. View

12.

Xu Y, Ma M, Ippolito G, Schroeder Jr H, Carroll M, Volanakis J . Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A. 2001; 98(25):14577-82. PMC: 64724. DOI: 10.1073/pnas.261428398. View

13.

IKARI N, Sakai Y, Hitomi Y, Fujii S . New synthetic inhibitor to the alternative complement pathway. Immunology. 1983; 49(4):685-91. PMC: 1454324. View

14.

Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams C . Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019; 116(16):7926-7931. PMC: 6475383. DOI: 10.1073/pnas.1820892116. View

15.

Riedl M, Thorner P, Licht C . C3 Glomerulopathy. Pediatr Nephrol. 2016; 32(1):43-57. DOI: 10.1007/s00467-015-3310-4. View

16.

Ponnuraj K, Xu Y, Macon K, Moore D, Volanakis J, Narayana S . Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell. 2004; 14(1):17-28. DOI: 10.1016/s1097-2765(04)00160-1. View

17.

Risitano A, Marotta S, Ricci P, Marano L, Frieri C, Cacace F . Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol. 2019; 10:1157. PMC: 6587878. DOI: 10.3389/fimmu.2019.01157. View

18.

Matsumoto M, Fukuda W, Circolo A, Goellner J, Strauss-Schoenberger J, Wang X . Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci U S A. 1997; 94(16):8720-5. PMC: 23097. DOI: 10.1073/pnas.94.16.8720. View

19.

Vulpetti A, Randl S, Rudisser S, Ostermann N, Erbel P, Mac Sweeney A . Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors. J Med Chem. 2017; 60(5):1946-1958. DOI: 10.1021/acs.jmedchem.6b01684. View

20.

Halawa O, Lin J, Miller J, Vavvas D . A Review of Completed and Ongoing Complement Inhibitor Trials for Geographic Atrophy Secondary to Age-Related Macular Degeneration. J Clin Med. 2021; 10(12). PMC: 8230644. DOI: 10.3390/jcm10122580. View